Serum Cystatin C Levels are Positively Associated with Cardiovascular Autonomic Neuropathy in Patients with Type 2 Diabetes

 

 Buy Article Permissions and Reprints

Abstract

Aims: Previous studies have reported that cystatin C is associated with degenerative disorder in the nervous system. However, the relationship between serum cystatin C concentrations and cardiovascular autonomic neuropathy (CAN) in patients with type 2 diabetes is currently unknown. The aim of this study was to assess the relationships between serum cystatin C levels and CAN in patients with type 2 diabetes.

Methods: A total of 357 patients with type 2 diabetes were studied in this cross-sectional study. CAN was diagnosed by a cardiovascular autonomic reflex test. According to the American Diabetes Association criteria, the degree of cardiovascular autonomic dysfunction was graded as normal, early, definite, or severe. CAN was either definite or severe in the subjects of the present study.

Results: Serum cystatin C concentrations were significantly higher in patients with CAN than in those without CAN. The mean cystatin C levels differed significantly according to the degree of cardiovascular autonomic dysfunction (normal, 0.78 mg/l; early, 0.79 mg/l; definite, 0.87 mg/l; severe, 0.90 mg/l; P for trend=0.021) after adjustment for other covariates. In multivariate analysis, serum cystatin C levels were significantly associated with CAN (odds ratio [OR] of each standard deviation increase in the logarithmic value, 5.25; 95% confidence interval [CI], 1.17–23.70, P=0.025).

Conclusions: Serum cystatin C levels are positively associated with CAN in patients with type 2 diabetes.

• References

• 1 Pop-Busui R. Cardiac autonomic neuropathy in diabetes: a clinical perspective. Diabetes Care 2010; 33: 434-441
  CrossrefPubMedGoogle Scholar
• 2 Vinik AI, Maser RE, Mitchell BD et al. Diabetic autonomic neuropathy. Diabetes Care 2003; 26: 1553-1579
  CrossrefPubMedGoogle Scholar
• 3 Mussap M, Dalla Vestra M, Fioretto P et al. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int 2002; 61: 1453-1461
  CrossrefPubMedGoogle Scholar
• 4 Taglieri N, Koenig W, Kaski JC et al. Cystatin C and cardiovascular risk. Clin Chem 2009; 55: 1932-1943
  CrossrefPubMedGoogle Scholar
• 5 Sahakyan K, Lee KE, Shankar A et al. Serum cystatin C and the incidence of type 2 diabetes mellitus. Diabetologia 2011; 54: 1335-1340
  CrossrefPubMedGoogle Scholar
• 6 Deng A, Irizarry MC, Nitsch RM et al. Elevation of cystatin C in susceptible neurons in Alzheimer’s disease. Am J Pathol 2001; 159: 1061-1068
  CrossrefPubMedGoogle Scholar
• 7 Nagai A, Ryu JK, Kobayash S et al. Cystatin C induces neuronal cell death in vivo. Ann N Y Acad Sci 2002; 977: 315-321
  CrossrefPubMedGoogle Scholar
• 8 Bollengier F. Cystatin C, alias post-gamma-globulin: a marker for multiple sclerosis?. J Clin Chem Clin Biochem 1987; 25: 589-593
  PubMedGoogle Scholar
• 9 Hu Y, Liu F, Shen J et al. Association between serum cystatin C and diabetic peripheral neuropathy: a cross-sectional study of a Chinese type 2 diabetic population. Eur J Endocrinol 2014; 171: 641-648
  CrossrefPubMedGoogle Scholar
• 10 Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612
  CrossrefPubMedGoogle Scholar
• 11 Isomaa B, Almgren P, Henricsson M et al. Chronic complications in patients with slowly progressing autoimmune type 1 diabetes (LADA). Diabetes Care 1999; 22: 1347-1353
  CrossrefPubMedGoogle Scholar
• 12 Kuehl M, Stevens MJ. Cardiovascular autonomic neuropathies as complications of diabetes mellitus. Nat Rev Endocrinol 2012; 8: 405-416
  CrossrefPubMedGoogle Scholar
• 13 Tesfaye S, Boulton AJ, Dyck PJ et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33: 2285-2293
  CrossrefPubMedGoogle Scholar
• 14 Kang SM, Ko KS, Ko SH et al. Management of diabetic neuropathy. Seoul: Korean Diabetes Association; 2011
  Google Scholar
• 15 Woitas RP, Kleber ME, Meinitzer A et al. Cystatin C is independently associated with total and cardiovascular mortality in individuals undergoing coronary angiography. The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Atherosclerosis 2013; 229: 541-548
  CrossrefPubMedGoogle Scholar
• 16 Ni L, Lu J, Hou LB et al. Cystatin C, associated with hemorrhagic and ischemic stroke, is a strong predictor of the risk of cardiovascular events and death in Chinese. Stroke 2007; 38: 3287-3288
  CrossrefPubMedGoogle Scholar
• 17 Ristiniemi N, Lund J, Tertti R et al. Cystatin C as a predictor of all-cause mortality and myocardial infarction in patients with non-ST-elevation acute coronary syndrome. Clin Biochem 2012; 45: 535-540
  CrossrefPubMedGoogle Scholar
• 18 Muntner P, Mann D, Winston J et al. Serum cystatin C and increased coronary heart disease prevalence in US adults without chronic kidney disease. Am J Cardiol 2008; 102: 54-57
  CrossrefPubMedGoogle Scholar
• 19 Donahue RP, Stranges S, Rejman K et al. Elevated cystatin C concentration and progression to pre-diabetes: the Western New York study. Diabetes Care 2007; 30: 1724-1729
  CrossrefPubMedGoogle Scholar
• 20 Sabanayagam C, Wong TY, Xiao J et al. Serum cystatin C and prediabetes in non-obese US adults. Eur J Epidemiol 2013; 28: 311-316
  CrossrefPubMedGoogle Scholar
• 21 He R, Shen J, Zhao J et al. High cystatin C levels predict severe retinopathy in type 2 diabetes patients. Eur J Epidemiol 28: 775-778
  PubMedGoogle Scholar
• 22 Ono S, Shimizu N, Imai T et al. Increased cystatin C immunoreactivity in the skin in amyotrophic lateral sclerosis. Acta Neurol Scand 2000; 102: 47-52
  PubMedGoogle Scholar
• 23 Nagai A, Ryu JK, Terashima M et al. Neuronal cell death induced by cystatin C in vivo and in cultured human CNS neurons is inhibited with cathepsin B. Brain Res 2005; 1066: 120-128
  CrossrefPubMedGoogle Scholar
• 24 Knight EL, Verhave JC, Spiegelman D et al. de Zeeuw D, Curhan GC, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004; 65: 1416-1421
  CrossrefPubMedGoogle Scholar
• 25 Stevens LA, Schmid CH, Greene T et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int 2009; 75: 652-660
  CrossrefPubMedGoogle Scholar
• 26 Shlipak MG, Katz R, Cushman M et al. Cystatin-C and inflammatory markers in the ambulatory elderly. Am J Med 2005; 118: 1416
  PubMedGoogle Scholar
• 27 Mussap M, Plebani M. Biochemistry and clinical role of human cystatin C. Crit Rev Clin Lab Sci 2004; 41: 467-550
  CrossrefPubMedGoogle Scholar
• 28 Surendar J, Indulekha K, Aravindhan V et al. Association of cystatin-C with metabolic syndrome in normal glucose-tolerant subjects (CURES-97). Diabetes Technol Ther 2010; 12: 907-912
  CrossrefPubMedGoogle Scholar
• 29 Demircan N, Gurel A, Armutcu F et al. The evaluation of serum cystatin C, malondialdehyde, and total antioxidant status in patients with metabolic syndrome. Med Sci Monit 2008; 14: CR97-CR101
  PubMedGoogle Scholar
• 30 Reffelmann T, Krebs A, Ittermann T et al. Mild renal dysfunction as a non-traditional cardiovascular risk factor? – Association of cystatin C-based glomerular filtration rate with flow-mediated vasodilation. Atherosclerosis 2010; 211: 660-666
  CrossrefPubMedGoogle Scholar
• 31 Stevens LA, Coresh J, Schmid CH et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008; 51: 395-406
  CrossrefPubMedGoogle Scholar